Ann: ATL1102 DMD Paediatric Investigation Plan submitted to EMA, page-41

First 41 Last

Share
Profile

Follow
moll76

115 Posts.

12

26/02/21

02:04

Post #: 51343622
Share

Originally posted by samfiodiving: ↑

So for those that could not quite grasp my calls on MC earlier

This is how Doug ingram Sareptas boss viewed the Roche deal at that time before it all fell over

Sarepta CEO Douglas Ingram estimated the total value of the deal could amount to $10 billion. "

He then moved on to say

The Sarepta deal came after a "robust, competitive process," Ingram said, although he did not reveal what other bidders were involved. Big pharma's interest in SRP-9001 was probably heightened by the struggles of other experimental gene therapies: Solid Biosciences' SGT-001 is under a clinical hold from the Food and Drug Administration and Pfizer's also has had safety complications

so obviously there was a huge amount of interest by other BIG PHARMAS in Sareptas drug

Why

Because of the struggles of other gene therapies in the same space

WOW that was then

So in light of other failures recently highlighted by members of this forum, plus the market leader in Sareptas failure recently

Just imagine then, Sarepta were involved in a bidding war for their drug still in trial pre ph2

The question to ask is how many of the

BIG PHARMAS interested in Sareptas drug are now involved

In a bidding war, and in extended due diligence on our results and trial data from the succesful ph2 trial completed with outstanding results in the DMD space that have never been achieved in any previous trials

Please take note once more

Doug Ingram's quote

The deal could have amounted to
$10 billion

that was for 50% of the world rights

You tell me what we are worth

Yeah I know

18c yeah right lol

Andy

Those 3c days were the days my friend lol

See how we go

Expand

I have added your interesting contribution to our Wall Street Online board in Germany

ANP Price at posting: 18.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

PAM

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

RAD

Radiopharm extends radioimmunotherapy trial to 5 more cancer types

SGP

Things finally 'looking different' for up-and-down Hot Stock tip Stockland

First 41 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 7.8¢		Change -0.003(3.70%)		Mkt cap ! $82.67M

Open	High	Low	Value	Volume
8.1¢	8.1¢	7.8¢	$215.5K	2.715M

Buyers (Bids)

No.	Vol.	Price($)
2	137820	7.8¢

Sellers (Offers)

Price($)	Vol.	No.
8.0¢	319232	3

View Market Depth

No.	Vol.	Price($)
2	137820	0.078
4	308042	0.077
4	296000	0.076
6	732416	0.075
2	20313	0.074

Price($)	Vol.	No.
0.080	319232	3
0.081	188810	1
0.082	183268	1
0.083	37500	1
0.085	225000	1

Last trade - 15.59pm 19/11/2024 (20 minute delay)

PER (ASX) Chart

Ann: ATL1102 DMD Paediatric Investigation Plan submitted to EMA, page-41

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Radiopharm extends radioimmunotherapy trial to 5 more cancer types

Things finally 'looking different' for up-and-down Hot Stock tip Stockland

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: ATL1102 DMD Paediatric Investigation Plan submitted to EMA, page-41

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Radiopharm extends radioimmunotherapy trial to 5 more cancer types

Things finally 'looking different' for up-and-down Hot Stock tip Stockland

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News